Editas Medicine, Inc.·4

Sep 4, 4:21 PM ET

Burkly Linda 4

4 · Editas Medicine, Inc. · Filed Sep 4, 2025

Insider Transaction Report

Form 4
Period: 2025-09-03
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
  • Sale

    Common Stock

    2025-09-03$2.60/sh710$1,84369,490 total
Footnotes (2)
  • [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.
  • [F2]The amount of securities beneficially owned following the reported transaction includes 5,802 shares acquired under the Issuer's Employee Stock Purchase Plan.

Documents

1 file
  • 4
    wk-form4_1757017284.xmlPrimary

    FORM 4